Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on October 15, 2004. The filing discloses the completion of a private placement of equity securities that closed on October 13, 2004.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than operational financial performance metrics such as revenue or profit.
- Total Proceeds: Approximately $13.9 million.
- Common Stock Issued: 7,925,715 shares at a purchase price of $1.75 per share.
- Warrants Issued: Warrants to purchase an additional 2,377,715 shares.
- Warrant Terms: Exercise price of $2.25 per share; exercisable between April 15, 2005, and October 12, 2009.
- Investor Base: Institutional and accredited investors.
Material Changes
The primary material change is the increase in the company's capital base through the issuance of new equity and warrants. The filing does not provide comparative financial data (e.g., revenue or net income) against prior periods as this is a transaction-specific report.
Guidance, Outlook, and Risks
Management Commentary: The company has agreed to file a registration statement with the SEC to cover the resale of the shares issued in the private offering and shares issued upon the exercise of warrants.
Regulatory Status: The securities were sold pursuant to an exemption from registration under Regulation D of the Securities Act of 1933. No shareholder approval was required for this offering.
Risks/Contingencies: The filing text does not explicitly list new risks or contingencies beyond the standard terms of the warrant exercise period and the requirement to file a future registration statement.
Investor Verification Checklist
- Verify the final closing amount and exact number of shares issued against the $13.9 million estimate.
- Confirm the filing of the registration statement for the resale of shares as promised by management.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor the company's cash burn rate to assess how long the $13.9 million in proceeds will sustain operations.